Revista de Oncología

, Volume 6, Issue 6, pp 381–390 | Cite as

Tumor banks for genomic and proteomic research

  • David Olmos Hidalgo
  • Nuria Ribelles Entrena
Sección Docente


The information offered by the new techniques of genomics and proteomics will substantially modify diagnostic and therapeutic approaches to cancer. Nevertheless, this type of research is limited by the lack of available tissue samples. Tumor banks are support tools for transference investigation, providing rapid access to information and supplying the tissue samples required by a given research project. In this article, the purposes and applications of tumor banks are reviewed, as well as the ethical and legal principles that guide their operation.


Transference Investigation PROTEOMIC Research Royal Decree Tumor Bank Biomedical Investigation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Celis JE, Kruhoffer M, Gromova I, et al. Gene expression profiling: Monitoring transcription and traslation products using DNA microarrays and proteomics. FEBS Lett 2000;480:2–16.CrossRefPubMedGoogle Scholar
  2. 2.
    Celis JE. A new start in Madrid: Symposium on basic and traslational cancer research. EMBO Rep 2002;3:718–23.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinoma. Moll Cell Proteomics 2002;1:304–13.CrossRefGoogle Scholar
  4. 4.
    Celis JE, Gromov P. Proteomics in traslational cancer research: Towards an integrated approach. Cancer Cell 2003;3:9–15.CrossRefPubMedGoogle Scholar
  5. 5.
    Michener CM, Ardekani AM, Petricoin EF 3rd, Liotta LA, Kohn EC. Genomics and proteomics: Application of novel technology to early detection and prevention of cancer. Cancer Detect Prev 2002;26:249–55.CrossRefPubMedGoogle Scholar
  6. 6.
    Van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999–2009.CrossRefPubMedGoogle Scholar
  7. 7.
    Ma XJ, Salunga R, Tuggle JT, et al. Gene expresion profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003;100:5974–9.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ferea TL, Brown PO. Observing the living genome. Curr Opin Genet Dev 1999;9:715–22.CrossRefPubMedGoogle Scholar
  9. 9.
    Baak JPA, Path FRC, Hemsen MAJA, Meijer G, Schmidt J, Janssen EAM. Genomics and proteomics in cancer. Eur J Cancer 2003;39:1199–215.CrossRefPubMedGoogle Scholar
  10. 10.
    Hair JF, McNicol AM, Guterson BA. Is research on human tissues at a crossroads? Eur J Cancer 2003;39:2253–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Oosterhuis JW, Coebergh JW, van Veen EB. Tumor Banks: well-guarded treasures in the interest of patients. Nat Rev Cancer 2003;3:73–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Morente MM, Alonso S. Bancos de tumores y oncopatología en el siglo XXI. Red de bancos de tumores y programa de patología molecular del CNIO. V congreso virtual hispanoamericano de Anatomía Patológica; 2003, septiembre [online], (cited 14-03-2004). Available from: Scholar
  13. 13.
    Teodorovic I, Therasse P, Spatz A, Isabelle M, Oosterhuis W. Human tissue research: EORTC recommendations on its practical consequences. Eur J Cancer 2003;39:2256–63.CrossRefPubMedGoogle Scholar
  14. 14.
    Burbaum J, Tobal GM. Proteomics in drug discovery. Curr Opin Chem Biol 2002;26:249–55.Google Scholar
  15. 15.
    Witzmann FA, Grant RA. Pharmacoproteomics in drug development. Pharmacogenomics 2003;2:69–76.CrossRefGoogle Scholar
  16. 16.
    Bleicher KH, Bohm HJ, Mueller K, Alanine AI. Hit and lead generation: Beyond high-throughput screening. Nat Rev Drug Discov 2003;2:369–78.CrossRefPubMedGoogle Scholar
  17. 17.
    Becich MJ. The role of the patologist as tissue refiner and data miner: the impact of funtional genomics on the modern pathology laboratory and the critical roles of pathology informatics and bioinformatics. Mol Diagn 2000;5:287–99.CrossRefPubMedGoogle Scholar
  18. 18.
    Celis JE, Gromov P, Gromova I, et al. Integrating proteomic and funtional genomic technologies in discovery-driven traslational breast cancer research. Moll Cell Proteomics 2003;2:369–77.Google Scholar
  19. 19.
    Adam D. Online tumors banks aims to offer ready route to tissues. Nature 2002;416:64.CrossRefGoogle Scholar
  20. 20.
    Morente MM. La red de bancos de tumores. Programas cientificos del CNIO [on line]; (cited 14-03-2004). Available from: Scholar
  21. 21.
    Grady C. Ethics and genetic testing. Adv Intern Med 1999;44:348–411.Google Scholar
  22. 22.
    Burgess MM. Beyond Consent: ethical and social issues in genetic testing. Nat Rev Genet 2001;2:147–51.CrossRefPubMedGoogle Scholar
  23. 23.
    Genetic Interest Group. Confidentiality guidelines: confidentially and medical genetics [online] 1999; (cited 10-3-2004). Available from: Scholar
  24. 24.
    Reilly PR. Legal issues in Genomic Medicine. Nat Med 2001;7:268–71.CrossRefPubMedGoogle Scholar
  25. 25.
    Instrumento de ratificación del Convenio para la proteción de los derechos humanos y la dignidad del ser humano con res Oviedo, 4 de Abril de 1997. BOE n.o251 de 20 de Octubre de 1999.Google Scholar
  26. 26.
    UNESCO (1997). Universal Declaration of the Human Genoma and Human Rights [on line] 1997, November 11; París (cited 17-03-2004). Available from: Scholar
  27. 27.
    White MT. Underlaying ambiguities in genetic privacy legislation. Genet Testing 1999;3:341–5.CrossRefGoogle Scholar
  28. 28.
    Scully JL. Drawing a line: situating moral boundaries in genetic medicine. Bioethics 2001;15:189–204.CrossRefPubMedGoogle Scholar
  29. 29.
    Health Council (Gezondheidsraad). Towards proper use. The Hague: Gezondheidsraad, 1994.Google Scholar
  30. 30.
    Nuffield Council on Bioethics. Human tissue, Ethical and Legal issues. London: Nuffield Council on Bioethics, 1995.Google Scholar
  31. 31.
    Human Genomics Organisation (HUGO) Ethics Committee. Statement on DNA sampling: Control and Access [on line], 1998; (cited 17-03-2004). Available from: Scholar
  32. 32.
    European Group on Ethics and aspects of tissue banking, opinion no11, to the European Comission, 21 july 1998.Google Scholar
  33. 33.
    Medical Research Council of Canada, Natural Sciences and Engineering Research Council of Canada. Social Sciences and Humanities Research Council of Canada, Tri Council Policy Statement Ethical Conduct for research involving Human Subjects, especially section 10 [on line], 1998 (revised in 2000); (cited 17-03-2004). Available from: Scholar
  34. 34.
    National Bioethics Advisory Commission, research involving human biological materials: Ethical issues and policy guidance, Rockville, Maryland: National Bioethics Advisory Comission, vol. 1. [on line], August 1999; (cited 17-03-2004). Available from: Scholar
  35. 35.
    Medical Research Council. Human Tissue and biological samples of use in research. Medical Research Council, London [on line], 2001; (cited 17-03-2004). Available from: Scholar
  36. 36.
    Parlamento Europeo. Informe PE 300.127, de 8 de Noviembre de 2001, sobre las repercusiones éticas, jurídicas y económicas y sociales de la genética humana. Comisión Temporal sobre genética humana y otras nuevas tecnologías de la medicina moderna.Google Scholar
  37. 37.
    American College of Medical Genetics (ACMG). Rapid action task force on informed consent for genetic research. Statement on informed consent for genetic research. Am J Hum Genet 1996;59:471–4.Google Scholar
  38. 38.
    The National Human Genome Research Institute. Policy Recommendations [on line]; [cited 17-03-2004]. Available from: http://www.nhgri.nih.govGoogle Scholar
  39. 39.
    Statement of the WHO Expert Consultation on New Developments in Human Genetics. WHO-invited experts: 2000; July 20–21; Geneve [cited 17-03-2004]. Available from: http://www.who.intGoogle Scholar
  40. 40.
    Genetic Testing, Screening and “eugenics”. A genetic Interest Group Policy Paper [on line] 1999, November; (cited 17-03-2004). Available from: Scholar
  41. 41.
    NIH. Development of a Classification Methodology for Genetic Test: conclusions and recommendations of the Secretary' Advisory Committe on Genetic Testing [on line], 2001, September; (cited 17-03-2004). Available from: Scholar
  42. 42.
    Department of Health. Human Genetic Commission (HCG). Protection of genetic information: an international comparison [on line], 2000, September; (cited 17-03-2004). Available from: publications.htmlGoogle Scholar
  43. 43.
    Knoppers BM, Hirtle M, Lormeau S, Laberge CM, Laflamme M. Control of DNA samples and information. Genomics 1998;50:385–401.CrossRefPubMedGoogle Scholar
  44. 44.
    American Association of Medical Colleges (AAMC). Executive Council. Medical records and genetic privacy. Health data security, patient privacy, and the use of archival patient materials in research. Washington DC: American Medical Association, 1997.Google Scholar
  45. 45.
    American College of Medical Genetics (ACMG). Ad Hoc Committee on DNA Technology. DNA banking and DNA analysis. Points to consider. Am J Hum Genet 1988;42: 781–3.Google Scholar
  46. 46.
    Clayton EW, Steinberg KK, Khoury MJ, et al. Informed consent for genetic research on stored tissue samples. JAMA 1995;274:1786–92.CrossRefPubMedGoogle Scholar
  47. 47.
    European Society of Human Genetics. Public and Professional fessional Policy Committe (PPPC). Data storage and DNA banking for biomedical research. Proposed recommendations of the European Society of Human Genetics. August 2001.Google Scholar
  48. 48.
    UNESCO. International Bioethics Committee. Working Group of IBC on genetic Data. Draft Report on Collection, treatment, storage and use of genetic data. París, 2001 September.Google Scholar
  49. 49.
    UNESCO. International Bioethics Committee. Working Group of IBC on the follow-up of the International Symposium on Ethics, Intellectual Property and Genomics. Draft Report. August 2001.Google Scholar
  50. 50.
    The NCI-Cooperative Human Tissue Network (CHTN) requires compliance with the US DHHS policy for the protection of human subjects for use of tissue from the listed repositories [on.line]; (cited 17-03-2004). Available from: subjects/guidance/45cfr46.htmlGoogle Scholar
  51. 51.
    Baeyens AJ, Hakimian R, Spatz A, Aamodt R. Use of human biological samples in research: a comparison of the laws in the Use and Europe. Biosci Law Rev 2003; 11.Google Scholar
  52. 52.
    Declaración de Helsinki de la Asociación Médica Mundial. Principios éticos para las investigaciones médicas en seres humanos. Adoptada por la 18a Asamblea Médica Mundial. Finlandia 1964, Junio y posteriores revisiones (1975, 1983, 1989, 1996, 2000); Helsinki, [cited 17-03-2004]. Available from: Scholar
  53. 53.
    Rodríguez-Villanueva J, Alsarb MJ, Avedañoc C, Gómez-Piqueras C, García-Alonso F. Estudios farmacogenéticos: guía de evaluación para Comités Éticos de Investigación Clínica. Fundamentos científicos y marco legal. EE-CC Revista de los ensayos Clínicos [serial on line] 2003; (cited 17-03-2004). Available from: Scholar
  54. 54.
    The European Union. Directive 95/46/EC on the protection of individuals with regard to the processing of personal data and on the free movement of such data [on line]; (cited 11-03-2004). Available from: Scholar
  55. 55.
    Rynning E. The new swedish act on biobanks in health care-privacy versus freedom of research revisited. Book of Proceedings II, 14th World Congress on Medical Law: 2002, August 10–15; Maastricht. Maastrict: MECC, 2002.Google Scholar
  56. 56.
    Saul H. News. Eur J Cancer 2003;39:551–5.CrossRefGoogle Scholar
  57. 57.
    Theilade MD, Knudsen LE, Renneberg J. Regulatory requirements for inclusion of Pharmacogenetic testing in applications for clinical trials in Europe. Regul Affairs J 2001;12:92–9.Google Scholar
  58. 58.
    Loi no 88-1138 du 20 décembre 1988 relative à la protection des persones qui se prétent à des recherches biomédicales (Journal Officiel, 22 décembre 1988) modifieé par la loi n0 90–86 du 23 janvier 1990 (Journal Officiel, 25 janvier 1990), la loi n0 90–549 du 2 julliet 1990 (Journal Officiel, 5).Google Scholar
  59. 59.
    Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine [on line]; (cited 17-03-2004). Available from: Scholar
  60. 60.
    Real Decreto 561/1993, 16 de Abril, por el que se establecen los requisitos para la realización de ensayos clínicos. BOE de 13 de mayo de 1993.Google Scholar
  61. 61.
    Ley orgánica 15/1999, de 13 de diciembre, de Protección de Datos de Carácter Personal. BOE de 14 de diciembre de 1999.Google Scholar
  62. 62.
    Directiva 95/46/CE del Parlamento Europeo y del Consejo de 24 de octubre de 1995, relativa a la protección de las personas. Diario Oficial de las Comunidades Europeas, 23 de noviembre de 1995, no L281:31-50.Google Scholar
  63. 63.
    Real Decreto 994/1999 de 11 de junio. Reglamento de medidas de seguridad de los ficheros automatizados que contengan datos de carácter personal. Ministerio de Justicia. BOE de 25 de junio de 1999.Google Scholar
  64. 64.
    Recomendación R (97) 5, de 13 de febrero de 1997, del Comité de Ministros del Consejo de Europa, 1997.Google Scholar
  65. 65.
    Rothstein MA, Epps PG. Ethical, and legal implications of pharmacogenomics. Nat Rev Genet 2001;2:238–41.CrossRefGoogle Scholar
  66. 66.
    March R, Cheeseman K, Diherty M. Pharmacogenetics-legal, ethical and regulatory considerations. Pharmacogenomics 2001;2:317–27.CrossRefPubMedGoogle Scholar
  67. 67.
    Robertson JA; Consent and Privacy in pharmacogenetic testing. Nat Genet 2001;28:207–9.CrossRefPubMedGoogle Scholar
  68. 68.
    Act on Biobanks No. 110/2000 [on line]; (cited 10-17-2004). Available from: Scholar
  69. 69.
    Federation of Medical Scientific Societies in The Netherlands. Code for proper use (FMWW, Rotterdam, 2002) [on line]; (cited 17-03-2004). Available from: http://www.fmw.nlGoogle Scholar
  70. 70.
    Owen D. Pateting human genes (National Institute for Medical Research) [on line]; (cited 17-03-2004). Available from: 1995/genepat.htmlGoogle Scholar
  71. 71.
    Directive 98/94/EC on the protection on biotechnological inventions, L.213/13 [on line]; (cited 17-03-2004). Available from: Scholar
  72. 72.
    Decision in case C-377/98 of the European Court of Justice [on line]; (cited 17-03-2004). Available from: Scholar
  73. 73.
    The President's Council on Bioethics. Pattenting Human Organisms. Staff Working Paper no 8 [on line]; (cited 17-04-2004). Available from: Scholar
  74. 74.
    Article 21 of The European Convention on Human Rights and Biomedicine [on line]; (cited 17-03-2004). Available from: CadreListeTraites.htmlGoogle Scholar
  75. 75.
    The NCI-CHTN, ref. 13 supra, policy on this subject [on line]; (cited 17-03-2004). Available from: Scholar
  76. 76.
    The NIH Guide for Grants and Contracts: Objectivity in Research [on line]; (cited 17-03-2004). Available from: Scholar
  77. 77.
    Massachusetts Institute of technology conflict of interest policy [on line]; (cited 17-03-2004). Available from: Scholar
  78. 78.
    International Committee of medical journals editors. Uniform requirements for manuscrispt submitted to medical journals. Ann Intern Med 1998;108:253–304.Google Scholar

Copyright information

© FESEO 2004

Authors and Affiliations

  • David Olmos Hidalgo
    • 1
  • Nuria Ribelles Entrena
    • 1
  1. 1.Medical Oncology ServiceHospital Clínico UniversitarioMálagaSpain

Personalised recommendations